CADL · ISSUER CIK 1841387
Candel Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 Candel Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $3.2M of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$3.2MInsider selling
−$3.2MNet open-market
Sep 11, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 202618:12 | Sep 11, 2026from Sep 10, 2026 | CADL | Chief Executive Officer, Director | S · Sell10b5-1 | $11.28 | −280,245 | 113,321 | -71% | −$3.2M | ||
| Sep 11, 202618:12 | Sep 10, 2026 | CADL | Chief Executive Officer, Director | M · Exercise10b5-1 | $1.55 | +125,000 | 393,566 | +47% | $194K | ||
| Aug 19, 202616:30 | Aug 17, 2026 | CADL | Chief Technology Officer | S · Sell10b5-1 | $12.00 | −7,000 | 76,865 | -8% | −$84K |